Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

The eight-week, quadruple-masked, dose-finding, core stage of the Phase 2b clinical trial is evaluating the efficacy and safety of a single ...

Future research will show whether the change in the availability of hallucinogens affects the risks associated with these ...

Ketamine is often viewed more as a party drug than a medicine. One Columbia clinic is using the drug to help patients with ...

Psychedelics have been recreational substances for decades. Now, they're entering the mainstream of psychiatric treatment.

Better Balance Psychiatry is redefining mental health care in Southern Utah with its personalized approach, advanced ...

Life Sciences (ATAI) announced the completion of patient enrollment in the eight-week, double-blind, core stage of the global Phase 2b ...

Glenmark Pharma recalled 1.48 million bottles of the generic attention deficit-hyperactivity disorder (ADHD) drug atomoxetine ...

Extended release bupropion hydrobromide, an oral monotherapy, is more effective in relieving symptoms of treatment resistant depression than past drugs.

Up to 300 New Zealanders a year are administered electric shock treatment – and the vast majority are happier for it.

Anova Enterprises, Inc. (Anova), a technology-enabled CRO dedicated to accelerating promising treatments, has announced enrollment of the first two pa ...

St John of God Hospital in Dublin has said it is the first hospital in Ireland to introduce a special treatment for patients ...